Hextan Y S Ngan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9069818/publications.pdf

Version: 2024-02-01

202 papers	8,154 citations	26567 56 h-index	66788 78 g-index
206 all docs	206 docs citations	206 times ranked	10903 citing authors

#	Article	IF	Citations
1	Update on the diagnosis and management of gestational trophoblastic disease. International Journal of Gynecology and Obstetrics, 2018, 143, 79-85.	1.0	268
2	Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis, 2008, 29, 1742-1750.	1.3	194
3	Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis, 2009, 30, 131-140.	1.3	180
4	Update on the diagnosis and management of gestational trophoblastic disease. International Journal of Gynecology and Obstetrics, 2015, 131, S123-6.	1.0	163
5	p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18622-18627.	3.3	161
6	Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. Nature Communications, 2018, 9, 2270.	5.8	159
7	Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer, 2006, 6, 212.	1.1	141
8	TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncology, The, 2009, 10, 772-784.	5.1	133
9	Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nature Genetics, 2006, 38, 38-46.	9.4	127
10	Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget, 2014, 5, 944-958.	0.8	120
11	The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: A quantitative study using laser-captured microdissected tissues. Gynecologic Oncology, 2005, 98, 104-110.	0.6	119
12	Tyrosine kinase B receptor and BDNF expression in ovarian cancers â€“ Effect on cell migration, angiogenesis and clinical outcome. Cancer Letters, 2009, 281, 151-161.	3.2	111
13	p70 S6 Kinase Promotes Epithelial to Mesenchymal Transition through Snail Induction in Ovarian Cancer Cells. Cancer Research, 2008, 68, 6524-6532.	0.4	107
14	The use of music to reduce anxiety for patients undergoing colposcopy: a randomized trial. Gynecologic Oncology, 2003, 91, 213-217.	0.6	105
15	Trophoblastic Disease Review for Diagnosis and Management: A Joint Report From the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. International Journal of Gynecological Cancer, 2014, 24, S109-S116.	1.2	105
16	Quality of Life in Women Treated with Neoadjuvant Chemotherapy for Advanced Ovarian Cancer: A Prospective Longitudinal Study. Gynecologic Oncology, 2003, 88, 9-16.	0.6	104
17	miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene, 2019, 38, 564-580.	2.6	103
18	MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. Molecular Cancer, 2017, 16, 11.	7.9	101

#	Article	IF	Citations
19	Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesisâ€"a differential expression and functional analysis. Carcinogenesis, 2009, 30, 114-121.	1.3	100
20	Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Research, 2002, 62, 4151-6.	0.4	98
21	Estrogen Receptor Subtypes in Ovarian Cancer. Obstetrics and Gynecology, 2008, 111, 144-151.	1.2	97
22	Beliefs about cervical cancer and human papillomavirus (HPV) and acceptability of HPV vaccination among Chinese women in Hong Kong. Preventive Medicine, 2007, 45, 130-134.	1.6	93
23	The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression. International Journal of Molecular Sciences, 2021, 22, 6560.	1.8	88
24	Pigment Epithelium-Derived Factor Is Estrogen Sensitive and Inhibits the Growth of Human Ovarian Cancer and Ovarian Surface Epithelial Cells. Endocrinology, 2006, 147, 4179-4191.	1.4	87
25	Diagnosis and management of gestational trophoblastic disease: 2021 update. International Journal of Gynecology and Obstetrics, 2021, 155, 86-93.	1.0	87
26	Trophoblastic disease. International Journal of Gynecology and Obstetrics, 2012, 119, S130-6.	1.0	85
27	Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades. Cancers, 2019, 11, 813.	1.7	83
28	Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecologic Oncology, 2004, 93, 435-440.	0.6	80
29	Mitochondrial DNA variant 16189T>C is associated with susceptibility to endometrial cancer. Human Mutation, 2003, 22, 173-174.	1.1	79
30	Evaluation of a Newly Developed GenoArray Human Papillomavirus (HPV) Genotyping Assay and Comparison with the Roche Linear Array HPV Genotyping Assay. Journal of Clinical Microbiology, 2010, 48, 758-764.	1.8	78
31	Aberrant Activation of ERK/FOXM1 Signaling Cascade Triggers the Cell Migration/Invasion in Ovarian Cancer Cells. PLoS ONE, 2011, 6, e23790.	1.1	77
32	Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer. Cancer Cell International, 2018, 18, 65.	1.8	77
33	Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis. Oncogene, 2005, 24, 3875-3885.	2.6	76
34	Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion. International Journal of Cancer, 2010, 127, 21-31.	2.3	76
35	Overexpression of Forkhead Box Protein M1 (FOXM1) in Ovarian Cancer Correlates with Poor Patient Survival and Contributes to Paclitaxel Resistance. PLoS ONE, 2014, 9, e113478.	1.1	76
36	Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene, 1999, 18, 4643-4646.	2.6	74

#	Article	IF	Citations
37	Overexpression of NANOG in Gestational Trophoblastic Diseases. American Journal of Pathology, 2008, 173, 1165-1172.	1.9	74
38	Paradoxical Impact of Two Folate Receptors, FRÎ± and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome. PLoS ONE, 2012, 7, e47201.	1.1	71
39	Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer. Molecular Cancer, 2009, 8, 70.	7.9	70
40	AMPK Activators Suppress Cervical Cancer Cell Growth through Inhibition of DVL3 Mediated Wnt/Î²-Catenin Signaling Activity. PLoS ONE, 2013, 8, e53597.	1.1	69
41	Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells. Communications Biology, 2019, 2, 281.	2.0	67
42	Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. International Journal of Cancer, 2008, 123, 296-302.	2.3	66
43	iASPP and Chemoresistance in Ovarian Cancers: Effects on Paclitaxel-Mediated Mitotic Catastrophe. Clinical Cancer Research, 2011, 17, 6924-6933.	3.2	66
44	Down-regulation of Sox7 is associated with aberrant activation of Wnt/Î²-catenin signaling in endometrial cancer. Oncotarget, 2012, 3, 1546-1556.	0.8	66
45	Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: A founder mutation of BRCA1 identified in the Chinese population. Human Mutation, 2002, 19, 307-308.	1.1	65
46	Knowledge, attitudes, and communication around human papillomavirus (HPV) vaccination amongst urban Asian mothers and physicians. Vaccine, 2010, 28, 3809-3817.	1.7	65
47	Promoter Hypermethylation of Multiple Genes in Hydatidiform Mole and Choriocarcinoma. Journal of Molecular Diagnostics, 2004, 6, 326-334.	1.2	64
48	Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase-related M30 CytoDeath antibody. Histopathology, 2001, 38, 243-249.	1.6	63
49	Perfusion and diffusion characteristics of cervical cancer based on intraxovel incoherent motion MR imaging-a pilot study. European Radiology, 2014, 24, 1506-1513.	2.3	61
50	Analysis of gestational trophoblastic disease by genotyping and chromosome in situ hybridization. Modern Pathology, 2004, 17, 40-48.	2.9	60
51	DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. Cancer Letters, 2018, 428, 104-116.	3.2	60
52	Prevalence and Risk Factors of Human Papillomavirus (HPV) Infection in Southern Chinese Women â€“ A Population-Based Study. PLoS ONE, 2011, 6, e19244.	1.1	59
53	Aberrant activation of hedgehog signaling pathway contributes to endometrial carcinogenesis through Î²-catenin. Modern Pathology, 2009, 22, 839-847.	2.9	58
54	Notice of Retraction. Carcinogenesis, 2011, 32, 765-771.	1.3	58

#	Article	IF	Citations
55	Establishment and Characterization of a Human First-Trimester Extravillous Trophoblast Cell Line (TEV-1). Journal of the Society for Gynecologic Investigation, 2005, 12, e21-e32.	1.9	58
56	Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas. Cancer Genetics and Cytogenetics, 2005, 157, 42-48.	1.0	56
57	Zic2 synergistically enhances Hedgehog signalling through nuclear retention of Gli1 in cervical cancer cells. Journal of Pathology, 2011, 225, 525-534.	2.1	56
58	miR-135a leads to cervical cancer cell transformation through regulation of Î²-catenin via a SIAH1-dependent ubiquitin proteosomal pathway. Carcinogenesis, 2014, 35, 1931-1940.	1.3	56
59	Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis. Histopathology, 2005, 46, 307-313.	1.6	54
60	Promoter Methylation and Differential Expression of Ï€-Class Glutathione S-Transferase in Endometrial Carcinoma. Journal of Molecular Diagnostics, 2005, 7, 8-16.	1.2	51
61	The effect of school-based cervical cancer education on perceptions towards human papillomavirus vaccination among Hong Kong Chinese adolescent girls. Patient Education and Counseling, 2011, 84, 118-122.	1.0	49
62	Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis. BMC Cancer, 2017, 17, 606.	1.1	49
63	Primary peritoneal malignant mixed Mï¿½llerian tumors. Cancer, 2001, 91, 1052-1060.	2.0	48
64	Tumour Suppressive Function and Modulation of Programmed Cell Death 4 (PDCD4) in Ovarian Cancer. PLoS ONE, 2012, 7, e30311.	1.1	48
65	Metastatic trophoblastic disease after an initial diagnosis of partial hydatidiform mole. Cancer, 2004, 100, 1411-1417.	2.0	46
66	Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis, 2006, 27, 1502-1506.	1.3	46
67	Endocrine Gland-Derived Vascular Endothelial Growth Factor Is Expressed in Human Peri-implantation Endometrium, But Not in Endometrial Carcinoma. Endocrinology, 2006, 147, 88-95.	1.4	46
68	Epigenetic and genetic alterations of p33 ING1b in ovarian cancer. Carcinogenesis, 2005, 26, 855-863.	1.3	45
69	Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells. PLoS ONE, 2012, 7, e52578.	1.1	45
70	Down-regulation and promoter methylation of tissue inhibitor of metalloproteinase 3 in choriocarcinoma. Gynecologic Oncology, 2004, 94, 375-382.	0.6	44
71	LY294002 and Metformin Cooperatively Enhance the Inhibition of Growth and the Induction of Apoptosis of Ovarian Cancer Cells. International Journal of Gynecological Cancer, 2012, 22, 15-22.	1.2	44
72	Chemotherapy in pregnancy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2016, 33, 86-101.	1.4	43

#	ARTICLE	IF	CITATIONS
73	Increased Expression of PITX2 Transcription Factor Contributes to Ovarian Cancer Progression. PLoS ONE, 2012, 7, e37076.	1.1	42
74	Oncogenic micro<scp>RNA</scp> signature for early diagnosis of cervical intraepithelial neoplasia and cancer. Molecular Oncology, 2018, 12, 2009-2022.	2.1	41
75	PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via Î±5Î²1 integrin and JNK/IL-8 signaling. Oncogenesis, 2020, 9, 24.	2.1	41
76	Semi-quantitative fluorescent PCR analysis identifies PRKAA1 on chromosome 5 as a potential candidate cancer gene of cervical cancer. Gynecologic Oncology, 2006, 103, 219-225.	0.6	40
77	Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-Î°B signaling. Oncotarget, 2014, 5, 7549-7562.	0.8	40
78	Epidemiology of Human Papillomavirus Infection and Cervical Cancer and Future Perspectives in Hong Kong, Singapore and Taiwan. Vaccine, 2008, 26, M60-M70.	1.7	39
79	Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. Molecular Cancer, 2010, 9, 318.	7.9	38
80	Differential Functions of Growth Factor Receptorâ€“Bound Protein 7 (GRB7) and Its Variant GRB7v in Ovarian Carcinogenesis. Clinical Cancer Research, 2010, 16, 2529-2539.	3.2	37
81	Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. Acta Obstetricia Et Gynecologica Scandinavica, 2011, 90, 445-451.	1.3	37
82	ERK Regulates HIF1Î±-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer. Clinical Cancer Research, 2019, 25, 5947-5960.	3.2	37
83	Minichromosome maintenance protein 7 expression in gestational trophoblastic disease: correlation with Ki67, PCNA and clinicopathological parameters. Histopathology, 2003, 43, 485-490.	1.6	36
84	Inhibition of Cervical Cancer Cell Growth through Activation of Upstream Kinases of AMP-Activated Protein Kinase. Tumor Biology, 2009, 30, 80-85.	0.8	36
85	Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade. Integrative Cancer Therapies, 2016, 15, 376-389.	0.8	35
86	Association of ICAM3 Genetic Variant with Severe Acute Respiratory Syndrome. Journal of Infectious Diseases, 2007, 196, 271-280.	1.9	33
87	Coexisting Epithelioid Trophoblastic Tumor and Choriocarcinoma of the Uterus Following a Chemoresistant Hydatidiform Mole. Archives of Pathology and Laboratory Medicine, 2003, 127, e291-e293.	1.2	33
88	Hypermethylation of SOX2 Gene in Hydatidiform Mole and Choriocarcinoma. Reproductive Sciences, 2008, 15, 735-744.	1.1	32
89	Transforming Growth Factor Î²1 Promotes Chromosomal Instability in Human Papillomavirus 16 E6E7â€“Infected Cervical Epithelial Cells. Cancer Research, 2008, 68, 7200-7209.	0.4	32
90	Coexistence of struma ovarii with marked ascites and elevated CA-125 levels: case report and literature review. Archives of Gynecology and Obstetrics, 2009, 279, 753-757.	0.8	31

#	Article	IF	Citations
91	Staging of uterine sarcomas. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 733-749.	1.4	31
92	Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. Oncogene, 2018, 37, 3981-3997.	2.6	31
93	Malignant placental site trophoblastic tumor. Cancer, 2002, 94, 2288-2294.	2.0	30
94	Effect of Individual Psychological Intervention in Chinese Women With Gynecologic Malignancy: A Randomized Controlled Trial. Journal of Clinical Oncology, 2005, 23, 4913-4924.	0.8	30
95	Frequent Occurrence of Mitochondrial Microsatellite Instability in the D-Loop Region of Human Cancers. Annals of the New York Academy of Sciences, 2005, 1042, 123-129.	1.8	28
96	Comparison of Human Papillomavirus DNA Levels in Gynecological Cancers: Implication for Cancer Development. Tumor Biology, 2003, 24, 310-316.	0.8	27
97	Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women. Journal of Medical Genetics, 2008, 46, 32-39.	1.5	27
98	ERBB2 mutation: A promising target in non-squamous cervical cancer. Gynecologic Oncology, 2018, 148, 311-316.	0.6	27
99	Symptoms, coping strategies, and timing of presentations in patients with newly diagnosed ovarian cancer. Gynecologic Oncology, 2003, 90, 651-656.	0.6	26
100	Mcl-1 expression in gestational trophoblastic disease correlates with clinical outcome. Cancer, 2005, 103, 268-276.	2.0	26
101	p21-Activated Kinase-1 Promotes Aggressive Phenotype, Cell Proliferation, and Invasion in Gestational Trophoblastic Disease. American Journal of Pathology, 2010, 176, 3015-3022.	1.9	24
102	Reduced expression of AMPK-Î²1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. Molecular Cancer, 2014, 13, 49.	7.9	24
103	HPV 16 E2 binding sites 1 and 2 become more methylated than E2 binding site 4 during cervical carcinogenesis. Journal of Medical Virology, 2015, 87, 1022-1033.	2.5	24
104	The mitosisâ€specific marker phosphohistoneâ€H3 (<scp>PHH</scp>3) is an independent prognosticator in uterine smooth muscle tumours: an outcomeâ€based study. Histopathology, 2017, 70, 746-755.	1.6	24
105	Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness. Journal of Pathology, 2018, 244, 151-163.	2.1	24
106	Primary Squamous Cell Carcinoma of Fallopian Tube. International Journal of Gynecological Pathology, 1994, 13, 92-95.	0.9	23
107	Asian society of gynecologic oncology workshop 2010. Journal of Gynecologic Oncology, 2010, 21, 137.	1.0	23
108	Cervical Cancer Burden and Prevention Strategies: Asia Oceania Perspective. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1414-1422.	1.1	23

#	ARTICLE	IF	CITATIONS
109	BRCA1 deficiency induces protective autophagy to mitigate stress and provides a mechanism for BRCA1 haploinsufficiency in tumorigenesis. Cancer Letters, 2014, 346, 139-147.	3.2	23
110	Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges. Acta Biochimica Et Biophysica Sinica, 2016, 48, 301-317.	0.9	23
111	Proliferation to apoptosis ratio as a prognostic marker in adenocarcinoma of uterine cervix. Gynecologic Oncology, 2004, 92, 866-872.	0.6	22
112	Single Nucleotide Polymorphism of Pi-Class Glutathione S-Transferase and Susceptibility to Endometrial Carcinoma. Clinical Cancer Research, 2005, 11, 2981-2985.	3.2	22
113	Downregulation of ASPP2 in choriocarcinoma contributes to increased migratory potential through Src signaling pathway activation. Carcinogenesis, 2013, 34, 2170-2177.	1.3	22
114	Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Medical Journal, 2010, 16, 171-9.	0.1	22
115	Gestational trophoblastic disease. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 357-370.	1.4	21
116	A Case Series of Five Patients With Pure or Mixed Gestational Epithelioid Trophoblastic Tumors and a Literature Review on Mixed Tumors. American Journal of Clinical Pathology, 2018, 150, 318-332.	0.4	20
117	Apoptosis and Anti-cancer Drug Discovery: The Power of Medicinal Fungi and Plants. Current Medicinal Chemistry, 2019, 25, 5613-5630.	1.2	20
118	Telomerase Assay and HPV 16/18 Typing as Adjunct to Conventional Cytological Cervical Cancer Screening. Tumor Biology, 2002, 23, 87-92.	0.8	18
119	FBI-1 Is Overexpressed in Gestational Trophoblastic Disease and Promotes Tumor Growth and Cell Aggressiveness of Choriocarcinoma via PI3K/Akt Signaling. American Journal of Pathology, 2015, 185, 2038-2048.	1.9	18
120	Single-dose methotrexate regimen in the treatment of low-risk gestational trophoblastic neoplasia. American Journal of Obstetrics and Gynecology, 2006, 195, 1282-1286.	0.7	17
121	Epigenetic Alteration of the Metallothionein 1E Gene in Human Endometrial Carcinomas. Tumor Biology, 2009, 30, 93-99.	0.8	17
122	Asia Oceania Guidelines for the Implementation of Programs for Cervical Cancer Prevention and Control. Journal of Cancer Epidemiology, 2011, 2011, 1-24.	0.5	17
123	Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients. Journal of Molecular Diagnostics, 2020, 22, 544-554.	1.2	17
124	Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers. Clinical Epigenetics, 2021, 13, 142.	1.8	17
125	Relapsed gestational trophoblastic neoplasia: A 20-year experience. Journal of reproductive medicine, The, 2006, 51, 829-34.	0.2	17
126	Distribution of Six Oncogenic Types of Human Papillomavirus and Type 16 Integration Analysis in Chinese Women with Cervical Precancerous Lesions and Carcinomas. Tumor Biology, 2008, 29, 105-113.	0.8	16

#	Article	IF	Citations
127	Ovarian Clear Cell Carcinoma With Choriocarcinomatous Differentiation. International Journal of Gynecological Pathology, 2010, 29, 539-545.	0.9	16
128	Overexpression of dedicator of cytokinesis I (Dock180) in ovarian cancer correlated with aggressive phenotype and poor patient survival. Histopathology, 2011, 59, 1163-1172.	1.6	16
129	Downregulation of ASPP1 in gestational trophoblastic disease: correlation with hypermethylation, apoptotic activity and clinical outcome. Modern Pathology, 2011, 24, 522-532.	2.9	16
130	Primary HPV testing with cytology versus cytology alone in cervical screeningâ€"A prospective randomized controlled trial with two rounds of screening in a Chinese population. International Journal of Cancer, 2020, 147, 1152-1162.	2.3	16
131	Role of Serial Tumor Markers in the Surveillance for Recurrence in Endometrial Cancer. Cancer Detection and Prevention, 1999, 23, 397-400.	2.1	16
132	Deâ€stigmatising human papillomavirus in the context of cervical cancer: a randomised controlled trial. Psycho-Oncology, 2010, 19, 1329-1339.	1.0	15
133	Id helix-loop-helix proteins are differentially expressed in gestational trophoblastic disease. Histopathology, 2005, 47, 303-309.	1.6	14
134	TAp73-Mediated the Activation of C-Jun N-Terminal Kinase Enhances Cellular Chemosensitivity to Cisplatin in Ovarian Cancer Cells. PLoS ONE, 2012, 7, e42985.	1.1	14
135	Age-period-cohort analysis of cervical cancer incidence in Hong Kong from 1972 to 2001 using maximum likelihood and Bayesian methods. Journal of Epidemiology and Community Health, 2006, 60, 712-720.	2.0	13
136	Detection of mosaic pattern of mitochondrial DNA alterations in different populations of cells from the same endometrial tumor. Mitochondrion, 2007, 7, 171-175.	1.6	13
137	Assessment of knowledge and stigmatizing attitudes related to human papillomavirus among Hong Kong Chinese healthcare providers. International Journal of Gynecology and Obstetrics, 2012, 116, 52-56.	1.0	13
138	SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance. Cell Death and Disease, 2021, 12, 341.	2.7	13
139	PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-Î°B Signaling Pathway in Ovarian Cancer. Frontiers in Oncology, 2022, 12, 748403.	1.3	13
140	COVIDâ€19 related fear and depression of pregnant women and new mothers. Public Health Nursing, 2022, 39, 562-571.	0.7	13
141	Detection of mitochondrial DNA mutations in gestational trophoblastic disease. Human Mutation, 2003, 22, 177-177.	1.1	12
142	Robot-assisted gynaecological cancer surgeryâ€"complications and prevention. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 45, 94-106.	1.4	12
143	Impact of different educational interventions on psychosocial well-being of women with a positive high-risk human papillomavirus and normal cervical cytology: a randomised trial. Journal of Psychosomatic Obstetrics and Gynaecology, 2018, 39, 146-155.	1.1	12
144	CD71+ Population Enriched by HPV-E6 Protein Promotes Cancer Aggressiveness and Radioresistance in Cervical Cancer Cells. Molecular Cancer Research, 2019, 17, 1867-1880.	1.5	12

#	Article	IF	Citations
145	Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases. Modern Pathology, 2020, 33, 138-152.	2.9	12
146	The expression of cathepsin D, oestrogen receptor and progestogen receptor in hydatidiform mole?an immunohistochemical study. Histopathology, 1995, 27, 341-347.	1.6	11
147	Who receives, benefits from and is harmed by cervical and breast cancer screening among Hong Kong Chinese?. Journal of Public Health, 2008, 30, 282-292.	1.0	11
148	Cyclophosphamide, Hydroxyurea, Actinomycin D, Methotrexate, and Vincristine in the Treatment of Gestational Trophoblastic Neoplasia. International Journal of Gynecological Cancer, 2015, 25, 498-503.	1.2	11
149	An Interactive Web-Based Sexual Health Literacy Program for Safe Sex Practice for Female Chinese University Students: Multicenter Randomized Controlled Trial. Journal of Medical Internet Research, 2021, 23, e22564.	2.1	11
150	Wide local excision (WLE) for vaginal intraepithelial neoplasia (VAIN). Acta Obstetricia Et Gynecologica Scandinavica, 1999, 78, 648-652.	1.3	10
151	Differential expression of insulin-like growth factor binding protein 1 and ferritin light polypeptide in gestational trophoblastic neoplasia. Cancer, 2005, 104, 2409-2416.	2.0	10
152	Comparison of the GenoFlow Human Papillomavirus (HPV) Test and the Linear Array Assay for HPV Screening in an Asian Population. Journal of Clinical Microbiology, 2012, 50, 1691-1697.	1.8	10
153	Differentiation of aggressive and indolent subtypes of uterine sarcoma using maximum standardized uptake value. Nuclear Medicine Communications, 2013, 34, 1185-1189.	0.5	10
154	Nurseâ€led followâ€up in survivorship care of gynaecological malignanciesâ€”A randomised controlled trial. European Journal of Cancer Care, 2020, 29, e13325.	0.7	10
155	Surgery including fertility-sparing treatment of GTD. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2021, 74, 97-108.	1.4	10
156	Functional tumour burden of peritoneal carcinomatosis derived from DWI could predict incomplete tumour debulking in advanced ovarian carcinoma. European Radiology, 2020, 30, 5551-5559.	2.3	10
157	Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-Î²B Axis. Cancers, 2021, 13, 4795.	1.7	10
158	Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets. Frontiers in Oncology, 2021, 11, 738177.	1.3	10
159	Diagnostic Performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and Expert Ultrasound Assessment in a Pelvic Mass Classified as Inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules. Cancers, 2022, 14, 810.	1.7	10
160	p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation. PLoS ONE, 2015, 10, e0133467.	1.1	9
161	Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. Oncotarget, 2018, 9, 7832-7843.	0.8	9
162	Amyloid Precursor Protein Overexpression in Down Syndrome Trophoblast Reduces Cell Invasiveness and Interferes with Syncytialization. American Journal of Pathology, 2018, 188, 2307-2317.	1.9	9

#	Article	IF	Citations
163	c-mos Immunoreactivity Aids in the Diagnosis of Gestational Trophoblastic Lesions. International Journal of Gynecological Pathology, 2004, 23, 145-150.	0.9	8
164	Human papillomavirus vaccine: What are women most concerned about?. Journal of Obstetrics and Gynaecology Research, 2012, 38, 23-30.	0.6	8
165	The role of laparoscopy in staging of different gynaecological cancers. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 884-895.	1.4	8
166	Association between MRI histogram features and treatment response in locally advanced cervical cancer treated by chemoradiotherapy. European Radiology, 2021, 31, 1727-1735.	2.3	8
167	Human Papillomavirus Self-Sampling for Primary Cervical Cancer Screening in Under-Screened Women in Hong Kong during the COVID-19 Pandemic. International Journal of Environmental Research and Public Health, 2022, 19, 2610.	1.2	8
168	Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers. International Journal of Molecular Sciences, 2022, 23, 6857.	1.8	8
169	Estimation of Fetal Weight in Utero from Symphysisfundal Height and Abdominal Girth Measurements. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1985, 25, 268-271.	0.4	7
170	Mitomycin C and Cisplatin Enhanced the Antitumor Activity of p53-Expressing Adenovirus in Cervical Cancer Cells. Cancer Investigation, 2001, 19, 360-368.	0.6	7
171	Combined electroacupuncture and auricular acupuncture for postoperative pain after abdominal surgery for gynecological diseases: study protocol for a randomized controlled trial. Trials, 2018, 19, 8.	0.7	7
172	MicroRNA-135a-induced formation of CD133+ subpopulation with cancer stem cell properties in cervical cancer. Carcinogenesis, 2020, 41, 1592-1604.	1.3	7
173	Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients. Cancers, 2021, 13, 4195.	1.7	7
174	A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer. Scientific Reports, 2022, 12, 3803.	1.6	7
175	The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment. Cancers, 2021, 13, 4577.	1.7	6
176	Vacuum Extractor: A Safe Instrument?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1986, 26, 177-181.	0.4	5
177	Screening for HIV infection in women with newly diagnosed cervical cancer. Gynecologic Oncology, 2004, 92, 300-303.	0.6	5
178	HPV vaccination in women over 25â€ƒyears of age: Asian Cervical Cancer Prevention Advisory Board recommendations. Journal of Obstetrics and Gynaecology Research, 2009, 35, 712-716.	0.6	5
179	Human Female Reproductive Tract Epithelial Cell Culture. Methods in Molecular Biology, 2012, 945, 347-363.	0.4	5
180	The Value of Contrast-Enhanced CT in the Detection of Residual Disease After Neo-Adjuvant Chemotherapy in Ovarian Cancer. Academic Radiology, 2020, 27, 951-957.	1.3	5

#	ARTICLE	IF	CITATIONS
181	Nuclear HKIIâ€“P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers, 2021, 13, 3399.	1.7	5
182	Methotrexate, Bleomycin, and Etoposide in the Treatment of Gestational Trophoblastic Neoplasia. Obstetrics and Gynecology, 2006, 107, 1012-1017.	1.2	4
183	Tamoxifen use in recurrent ovarian cancer in a Chinese population: A 15 â€year clinical experience in a tertiary referral center. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 338-342.	0.7	4
184	Radiomic Features of T2-weighted Imaging and Diffusion Kurtosis Imaging in Differentiating Clinicopathological Characteristics of Cervical Carcinoma. Academic Radiology, 2022, 29, 1133-1140.	1.3	4
185	A combination of electroacupuncture and auricular acupuncture for postoperative pain after abdominal surgery for gynaecological diseases: A randomized controlled trial. Phytomedicine, 2022, 104, 154292.	2.3	4
186	Mitomycin chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to gynecological cancer. Acta Obstetricia Et Gynecologica Scandinavica, 1999, 78, 443-446.	1.3	3
187	Section B: Malignant manifestations of HPV infection Carcinoma of the cervix, vulva, vagina, anus, and penis. International Journal of Gynecology and Obstetrics, 2006, 94, S50-S55.	1.0	3
188	Vulvar Hidradenitis Suppurativa: Is the Mass Malignant?. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 1.	0.3	3
189	Olaparib dose reâ€escalation in ovarian cancer patients who experienced severe and/or uncommon adverse events: A case series. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 3-11.	0.7	3
190	Primary peritoneal malignant mixed MÃ¼llerian tumors. , 2001, 91, 1052.		3
191	Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers. Journal of Ovarian Research, 2020, 13, 61.	1.3	3
192	Validating the use of the revised childbirth experience questionnaire in Hong Kong. BMC Pregnancy and Childbirth, 2022, 22, 126.	0.9	3
193	Diagnosis of Endometrial Carcinoma by Histopathological Examination of the Endometrial Aspirate by the Curity-Isaacs Sampler. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1987, 27, 234-237.	0.4	2
194	Potential Use of the Adenosine Triphosphate Cell Viability Assay in Endometrial Cancer. Journal of the Society for Gynecologic Investigation, 2006, 13, 518-522.	1.9	2
195	Association between High Diffusion-Weighted Imaging-Derived Functional Tumor Burden of Peritoneal Carcinomatosis and Overall Survival in Patients with Advanced Ovarian Carcinoma. Korean Journal of Radiology, 2022, 23, 539.	1.5	2
196	The Value of Cervical Punch Biopsy in the Assessment of Histopathological Prognostic Factors in Carcinoma of the Cervix. Asia-Oceania Journal of Obstetrics and Gynaecology, 1988, 14, 467-470.	0.0	1
197	Reproductive Performance of Patients with Gestational Trophoblastic Disease in Hong Kong. Obstetrical and Gynecological Survey, 1989, 44, 630.	0.2	0
198	Hepatic Arteriogram for Gestational Trophoblastic Tumor: Is It Useful?. Cancer Investigation, 2005, 23, 677-682.	0.6	0

#	ARTICLE	IF	CITATIONS
199	A4. Preinvasive lesions of the cervix. International Journal of Gynecology and Obstetrics, 2006, 94, S44-S49.	1.0	0
200	Preface. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 679.	1.4	0
201	Extremely stringent activation of p16INK4a prevents immortalization of uterine cervical epithelial cells without human papillomavirus oncogene expression. Oncotarget, 2016, 7, 45656-45670.	0.8	0
202	Fallopian tube carcinoma. , 0, , 779-789.		0